- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.10. | Mindmaze: Heimtherapie steigert Trainingsumfang dreifach | 23 | cash | ||
| MINDMAZE THERAPEUTICS HOLDING SA ADR Aktie jetzt für 0€ handeln | |||||
| 14.10. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch | 1.074 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Study results
MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch
14.10.2026... ► Artikel lesen | |
| 17.09. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Announces MindMotion Lite to Expand Home-Based Neurorehabilitation | 2.022 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Market Launch
MindMaze Therapeutics Announces MindMotion Lite to Expand Home-Based Neurorehabilitation
17-Sep-2026 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 01.09. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences | 807 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Conference
MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences
01.09.2026 / 07:00 CET/CEST
MindMaze... ► Artikel lesen | |
| 28.08. | MindMaze Therapeutics Holding SA H1 Sales Increase | 26 | RTTNews | ||
| 27.08. | Mindmaze noch mit Verlust, aber sieht grosses Potenzial | 650 | Moneycab | Lausanne - Mindmaze hat im ersten Halbjahr einen im Vorjahresvergleich höheren Verlust geschrieben. Dabei interessieren bei dem noch jungen Health-Tech-Unternehmen insbesondere die Barmittel und die... ► Artikel lesen | |
| 27.08. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update | 1.775 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Half Year Results
MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update
27-Aug-2026 / 07:00 CET/CEST
Release of an ad... ► Artikel lesen | |
| 12.08. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor | 1.064 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Miscellaneous
MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
12.08.2026 / 07:00 CET/CEST
MindMaze... ► Artikel lesen | |
| 10.08. | Mindmaze schliesst Vereinfachung der Organisation ab | 664 | Moneycab | Genf - Das Genfer Biotechunternehmen Mindmaze hat die Vereinfachung seiner Organisation abgeschlossen. Dabei hat es sich von praktisch allen verbliebenen nicht-neurologischen Aktivitäten getrennt, die... ► Artikel lesen | |
| 10.08. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing | 2.605 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Miscellaneous
MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing
10-Aug-2026... ► Artikel lesen | |
| 09.07. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy | 813 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Study
MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal... ► Artikel lesen | |
| 01.07. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe | 680 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Study
MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe... ► Artikel lesen | |
| 25.06. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Announces Results of Annual General Meeting | 819 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): AGMEGM
MindMaze Therapeutics Announces Results of Annual General Meeting
25.06.2026 / 12:50 CET/CEST
MindMaze Therapeutics... ► Artikel lesen | |
| 03.06. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting | 865 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): AGMEGM
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
03.06.2026 / 06:45 CET/CEST
MindMaze... ► Artikel lesen | |
| 02.06. | MindMaze Therapeutics verkauft Non-Core-Asset und senkt Kosten um ein Drittel | 34 | Investing.com Deutsch | ||
| 02.06. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification | 2.069 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Miscellaneous
MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification
02-Jun-2026 / 06:45 CET/CEST
Release... ► Artikel lesen | |
| 26.05. | MindMaze Therapeutics: CHF 8,0 Mio. strategische Eigenkapitalfinanzierung | 18 | Investing.com Deutsch | ||
| 26.05. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing | 2.031 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Financing
MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing
26-May-2026 / 06:50 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 12.05. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S. | 1.907 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Partnership
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across... ► Artikel lesen | |
| 30.04. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision Neurotherapeutics in the U.S. | 845 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Partnership
MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REVIVE THERAPEUTICS | 0,011 | +144,44 % | Revive Therapeutics Ltd.: Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases | Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs TORONTO, ON / ACCESS Newswire / September 15,... ► Artikel lesen | |
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 |
MINDMAZE THERAPEUTICS HOLDING SA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,003 (+1,76 %) liegt der Kurs bei 0,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINDMAZE THERAPEUTICS HOLDING SA ADR finden Sie auf Wallstreet Online.